Your browser doesn't support javascript.
loading
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.
Amaria, Rodabe N; Menzies, Alexander M; Burton, Elizabeth M; Scolyer, Richard A; Tetzlaff, Michael T; Antdbacka, Robert; Ariyan, Charlotte; Bassett, Roland; Carter, Brett; Daud, Adil; Faries, Mark; Fecher, Leslie A; Flaherty, Keith T; Gershenwald, Jeffrey E; Hamid, Omid; Hong, Angela; Kirkwood, John M; Lo, Serigne; Margolin, Kim; Messina, Jane; Postow, Michael A; Rizos, Helen; Ross, Merrick I; Rozeman, Elisa A; Saw, Robyn P M; Sondak, Vernon; Sullivan, Ryan J; Taube, Janis M; Thompson, John F; van de Wiel, Bart A; Eggermont, Alexander M; Davies, Michael A; Ascierto, Paolo A; Spillane, Andrew J; van Akkooi, Alexander C J; Wargo, Jennifer A; Blank, Christian U; Tawbi, Hussein A; Long, Georgina V.
Afiliação
  • Amaria RN; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Menzies AM; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia; Department of Medical Oncology, Mater Hospital Sydney, Sydney, NSW, Australia.
  • Burton EM; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Scolyer RA; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, Australia.
  • Tetzlaff MT; Department of Pathology and Translational and Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Antdbacka R; Birdie Pharmaceuticals, Iselin, NJ, USA.
  • Ariyan C; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
  • Bassett R; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Carter B; Department of Diagnostic Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Daud A; University of California San Francisco, San Francisco, CA, USA.
  • Faries M; The Angeles Clinic and Research Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA.
  • Fecher LA; University of Michigan, Ann Arbor, MI, USA.
  • Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
  • Gershenwald JE; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hamid O; The Angeles Clinic and Research Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA.
  • Hong A; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, Australia.
  • Kirkwood JM; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA.
  • Lo S; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia.
  • Margolin K; City of Hope, Duarte, CA, USA.
  • Messina J; Moffitt Cancer Center, Tampa, FL, USA.
  • Postow MA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA; Department of Medicine, Weill Cornell Medical College, New York City, NY, USA.
  • Rizos H; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Macquarie University, Sydney, Australia.
  • Ross MI; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Rozeman EA; Department of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands.
  • Saw RPM; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Department of Melanoma Surgery, Mater Hospital Sydney, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, Australia.
  • Sondak V; Moffitt Cancer Center, Tampa, FL, USA.
  • Sullivan RJ; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
  • Taube JM; Johns Hopkins Hospital, Baltimore, MD, USA.
  • Thompson JF; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Department of Melanoma Surgery, Mater Hospital Sydney, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, Australia.
  • van de Wiel BA; Department of Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands.
  • Eggermont AM; Department of Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands.
  • Davies MA; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ascierto PA; Experimental Medical Oncology for Melanoma, Cancer Immunotherapy and Development Therapeutics-Istituto Nazionale Tumouri IRCCS Fondazione Pascale, Napoli, Italy.
  • Spillane AJ; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Department of Surgical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia; Department of Melanoma Surgery, Mater Hospital Sydney, Sydney, NSW, Australia.
  • van Akkooi ACJ; Department of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands.
  • Wargo JA; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Blank CU; Department of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, Netherlands.
  • Tawbi HA; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Long GV; Melanoma Institute of Australia, The University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia; Department of Medical Oncology, Mater Hospital Sydney, Sydney, NSW, Australia. Electronic address: georgina.long@sydney.edu.au.
Lancet Oncol ; 20(7): e378-e389, 2019 07.
Article em En | MEDLINE | ID: mdl-31267972
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia Neoadjuvante / Melanoma Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia Neoadjuvante / Melanoma Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido